About one in four patients taking pergolide or cabergoline show signs of heart-valve damage according to two studies.
A U.S. official to call for a halt in the use of two drugs used for Parkinson’s disease, pergolide and cabergoline due to an increased risk of heart-valve damage.
Patients who took pergolide or cabergoline are four to seven times as likely to suffer heart-valve damage as patients who did not, reported two studies in Thursday’s New England Journal of Medicine.
In a British study, 19 percent of patients taking pergolide or cabergoline suffered heart-valve damage. An Italian study found heart-valve damage in 23 percent of patients who took pergolide and almost 29 percent for those prescribed cabergoline.
Click here to read the full report from National Institutes of Health
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.